Clinical Trials

We fund clinical trials to bring pioneering new therapies to leukaemia patients more quickly

Nurse and patient with leukaemia - part of Leuka's leukaemia research and treatment

Leuka backs clinical trials that are bringing pioneering and effective new therapies to leukaemia patients both here in the UK and abroad.

Clinical trials are designed to ensure groundbreaking new drugs are safe and effective and our funding means that some patients are able to access new treatments not yet available elsewhere.

From breakthrough to bedside

Clinical trials test new drugs and therapies in patients. These are vital to ensure that breakthroughs in the laboratory make the transition to the hospital ward or clinic.

If it wasn’t for research, which Leuka funds, I would never have received life-saving treatment

Michael Evans – leukaemia patient and Leuka supporter

Impact logo

IMPACT Trials Network

We are proud to be a part of the IMPACT stem cell transplant clinical trials network. This partnership aims to bring new drug and cellular therapies to patients.

Increasingly, people with leukaemia and other blood cancers can benefit from the availability of Stem Cell Transplantation (SCT) treatments. However, all too often those who have undergone SCT will eventually succumb to adverse reactions from the procedure. Of those who receive a stem cell transplant from an unrelated donor, fewer than 50% of them will reach the 5-year survival milestone.

That is why we’ve invested in a new clinical trials initiative called IMPACT to fast-track the testing of drug and cellular therapies for patients who suffer complications. 

Working in partnership with Anthony Nolan and NHS Blood and Transplant, we launched the initiative in November 2017.

Based at the University of Birmingham, the IMPACT partnership will work alongside specialist centres around the UK to provide the infrastructure for early phase clinical trials.

To find out more, visit the IMPACT website here: www.impactpartnership.org.uk

This much-needed initiative is possible through the collaboration of all the partners – with everyone totally focused on the goal of helping patients.

Professor David Marks, IMPACT medical director